17 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25555732	52	Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.	Xenon Pharmaceuticals
24374272	48	Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.	Xenon Pharmaceuticals
24370012	47	Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.	Xenon Pharmaceuticals
23265904	54	Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).	Merck Research Laboratories
23245208	91	Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.	Xenon Pharmaceuticals
21661758	39	Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.	Merck Frosst Centre For Therapeutic Research
17530838	50	Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.	Abbott Laboratories
22047692	50	Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.	Merck Frosst Centre For Therapeutic Research
22209206	35	Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.	Merck Frosst Centre For Therapeutic Research
21356569	20	Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.	Daiichi Sankyo
20801551	34	Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.	Daiichi Sankyo
20006498	67	Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].	Daiichi Sankyo
19926281	56	Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.	Daiichi Sankyo
19540759	61	Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.	Daiichi Sankyo
19541482	37	Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.	Daiichi Sankyo
18632269	18	Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.	Abbott Laboratories
30248655	64	Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.	Japan Tobacco